Denali Therapeutics Stock News
A form 4 filing from the u.s. Denali therapeutics reports third quarter 2021 financial results and business highlight.
Why denali therapeutics stock is sinking today.
Denali therapeutics stock news. President and ceo of denali therapeutics sold $1.00 million in stock. The decline came after the company. On average, they expect denali therapeutics' stock price to reach $93.29 in the next year.
Press release reported 23 hours ago that denali therapeutics announces positive interim data from phase 1/2 study with etv:ids (dnl310) in patients with the lysosomal. (dnli) came out with a quarterly loss of $0.69 per share versus the zacks consensus estimate of a loss of $0.51. Watts sold 18,333 shares of the stock in a transaction that occurred on wednesday, december 1st.
In other denali therapeutics news, ceo ryan j. The stock had previously closed at $54.10, but opened at $50.71. Oppenheimer has initiated shares of denali therapeutics with a buy rating saying the company is an underappreciated emerging leader in neurodegeneration and cns disorders.
(nasdaq:dnli) gapped down prior to trading on tuesday after an insider sold shares in the company. Shares of denali therapeutics inc. Reports earnings results for the third quarter and nine months.
Over 50 finance july 26, 2021 comments off. Shares of denali therapeutics ( nasdaq:dnli) had sunk 11.2% as of 12:02 p.m. The stock had previously closed at $54.10, but opened at $50.71.
Shares of denali therapeutics (nasdaq: (nasdaq:dnli) gapped down prior to trading on tuesday after an insider sold shares in the company. With a price/earnings ratio of 223.47, denali therapeutics inc p/e ratio is greater than that of about 96.7% of stocks in our set with positive earnings.
Denali therapeutics started at outperform with $85 stock price target at oppenheimer. Denali therapeutics unveiled promising test results in hunter syndrome, but dnli stock tanked on monday as investors questioned the viability of the biotech's broader platform. Denali therapeutics (nasdaq:dnli) shares gap down following insider selling.
This suggests a possible upside of 98.0% from the stock's current price. Earnings flash (dnli) denali therapeutics reports q3 revenue $5.3m. The shares were sold at an average price of $44.92, for a total transaction of $823,518.36.
Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Get the latest stock news for nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, investment community, individual investors and the general public. Denali therapeutics shares last traded at $52.87, with a volume of 2,179 shares traded.
Home news why denali therapeutics stock is sinking today. Denali therapeutics (nasdaq:dnli) shareholder returns have been stellar, earning 206% in 3 years. Securities and exchange commission on wednesday showed.
Get the latest denali therapeutics stock price and detailed information including dnli news, historical charts and realtime prices. Shares of denali therapeutics inc. Dnli) had sunk 11.2% as of 12:02 p.m.
8 brokerages have issued 1 year target prices for denali therapeutics' shares. The decline came after the company presented interim results on sunday from a phase 1/2 study evaluating. 06:01am, thursday, 11'th nov 2021 dakota financial news.
Their forecasts range from $70.00 to $111.00. Data is currently not available. Dnli | complete denali therapeutics inc.
Dakota financial news | november 14, 2021. Tweet on twitter share on facebook google+ pinterest. Ryan watts, president and ceo at denali therapeutics (nasdaq:dnli), made a large insider sell on september 1, according to a new sec filing.
Of note is the ratio of denali therapeutics inc's sales and general administrative expense to its total operating expenses;
Posting Komentar untuk "Denali Therapeutics Stock News"